Related Experiment Video
Updated: Jun 6, 2026
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Nutlin-3a is a potential therapeutic for ewing sarcoma
Kathleen I Pishas1, Fares Al-Ejeh, Irene Zinonos
1Sarcoma Research Group, Discipline of Medicine, University of Adelaide and Hanson Institute Adelaide, South Australia.
Purpose:
Although mutations in the TP53 gene occur in half of all cancers, approximately 90% of Ewing sarcomas retain a functional wild-type p53. The low frequency of TP53 alterations in Ewing sarcoma makes this tumor type an ideal candidate for p53-targeted therapies. In this study, we have examined the molecular and cellular responses of cultured Ewing sarcoma cell lines following exposure to Nutlin-3a, a recently developed MDM2 antagonist.
Experimental Design:
The ability of Nutlin-3a to impart apoptosis or cell cycle arrest in a p53-dependent manner was determined in a comprehensive panel of Ewing sarcoma cell lines. The capacity of Nutlin-3a to augment the antitumor activity of MDM4 antagonists and cytotoxic agents currently used in the clinical treatment of Ewing sarcoma was also investigated.
Results:
Apoptosis was the primary response of wild-type p53 expressing Ewing sarcoma cell lines. The cytotoxicity of Nultin-3a was also synergistic with the chemotherapeutic agents, vincristine, actinomycin D, doxorubicin, and etoposide in a concentration-dependent manner. Significant MDM4 protein overexpression was observed in Ewing sarcoma cell lines of wild-type p53 status, providing a mechanism through which Ewing sarcomas can develop in the absence of TP53 alterations. This study provides the first evidence of synergism between targeted inhibition of MDM2 and MDM4.
Conclusion:
Our findings suggest that p53-dependent apoptosis is the primary cellular response of Ewing sarcoma cell lines following exposure to Nutlin-3a. Furthermore, Nutlin-3a can synergize with the current Ewing sarcoma chemotherapy protocols, suggesting p53 activation as a novel systemic therapeutic approach for this disease.
Insights
Nutlin-3a induces apoptosis in Ewing sarcoma cells by activating p53. This drug synergizes with standard chemotherapy, offering a new therapeutic strategy for Ewing sarcoma by targeting p53.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Ewing sarcoma rarely harbors TP53 gene mutations, retaining functional wild-type p53.
- This characteristic makes Ewing sarcoma a promising candidate for therapies targeting the p53 pathway.
- MDM2 and MDM4 proteins inhibit p53 function.
Purpose of the Study:
- To investigate the effects of Nutlin-3a, an MDM2 antagonist, on Ewing sarcoma cell lines.
- To determine if Nutlin-3a can enhance the efficacy of existing Ewing sarcoma treatments.
- To explore the role of p53 activation in Ewing sarcoma response to therapy.
Main Methods:
- Assessed apoptosis and cell cycle arrest in Ewing sarcoma cell lines treated with Nutlin-3a.
- Evaluated the combined effects of Nutlin-3a with MDM4 antagonists and standard chemotherapeutic agents.
- Analyzed p53-dependent responses to Nutlin-3a exposure.
Main Results:
- Nutlin-3a induced apoptosis in Ewing sarcoma cell lines with wild-type p53.
- Nutlin-3a demonstrated synergistic cytotoxicity with vincristine, actinomycin D, doxorubicin, and etoposide.
- Observed MDM4 protein overexpression in wild-type p53 Ewing sarcoma, suggesting a compensatory mechanism.
Conclusions:
- p53-dependent apoptosis is the primary cellular response to Nutlin-3a in Ewing sarcoma.
- Nutlin-3a shows potential for synergistic effects with current Ewing sarcoma chemotherapy regimens.
- p53 activation represents a novel therapeutic strategy for Ewing sarcoma.
